Close

miRagen Therapeutics (MGEN) Say Data Shows Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies

April 27, 2018 7:12 AM EDT Send to a Friend
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced new ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login